{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:08:46Z","timestamp":1770250126065,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112\u20112314\u2011B\u2011650\u2011001\u2011MY3"],"award-info":[{"award-number":["NSTC 112\u20112314\u2011B\u2011650\u2011001\u2011MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00436-0","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:45:09Z","timestamp":1767757509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation"],"prefix":"10.1186","volume":"12","author":[{"given":"Chi-Hsien","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiow-Ing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank S.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Ju","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"436_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.12997\/jla.2023.12.1.37","volume":"12","author":"KA Kim","year":"2023","unstructured":"Kim KA, Park HJ. New therapeutic approaches to the treatment of dyslipidemia 2: LDL-C and Lp(a). J Lipid Atheroscler. 2023;12:37\u201346.","journal-title":"J Lipid Atheroscler"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.18433\/jpps31197","volume":"23","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Hu X, Zhang Y, Liu D. Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A systematic review and Meta-Analysis. J Pharm Pharm Sci. 2020;23:422\u201336.","journal-title":"J Pharm Pharm Sci"},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"713007","DOI":"10.3389\/fphar.2021.713007","volume":"12","author":"W Ma","year":"2021","unstructured":"Ma W, Pan Q, Pan D, Xu T, Zhu H, Li D. Efficacy and safety of Lipid-Lowering drugs of different intensity on clinical outcomes: A systematic review and network Meta-Analysis. Front Pharmacol. 2021;12:713007.","journal-title":"Front Pharmacol"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","volume":"138","author":"E Sliz","year":"2018","unstructured":"Sliz E, Kettunen J, Holmes MV, et al. Metabolomic consequences of genetic Inhibition of PCSK9 compared with Statin treatment. Circulation. 2018;138:2499\u2013512.","journal-title":"Circulation"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"175721","DOI":"10.1016\/j.ejphar.2023.175721","volume":"949","author":"PP Oza","year":"2023","unstructured":"Oza PP, Kashfi K. The evolving landscape of PCSK9 Inhibition in cancer. Eur J Pharmacol. 2023;949:175721.","journal-title":"Eur J Pharmacol"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","volume":"30","author":"S Spolitu","year":"2019","unstructured":"Spolitu S, Dai W, Zadroga JA, Ozcan L. Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism. Curr Opin Lipidol. 2019;30:186\u201391.","journal-title":"Curr Opin Lipidol"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40164-021-00218-1","volume":"10","author":"S-Z Zhang","year":"2021","unstructured":"Zhang S-Z, Zhu X-D, Feng L-H, Li X-L, Liu X-F, Sun H-C. Tang Z-Y. PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma. Experimental Hematol Oncol. 2021;10:25.","journal-title":"Experimental Hematol Oncol"},{"key":"436_CR8","doi-asserted-by":"crossref","unstructured":"Fasolato S, Pigozzo S, Pontisso P, et al. PCSK9 levels are Raised in chronic HCV patients with hepatocellular carcinoma. J Clin Med. 2020;9(10):3134.","DOI":"10.3390\/jcm9103134"},{"key":"436_CR9","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","volume":"13","author":"CC Wong","year":"2022","unstructured":"Wong CC, Wu J-L, Ji F, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer. Nat Commun. 2022;13:3971.","journal-title":"Nat Commun"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1158\/0008-5472.CAN-11-0568","volume":"71","author":"SJ Pitteri","year":"2011","unstructured":"Pitteri SJ, Kelly-Spratt KS, Gurley KE, et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res. 2011;71:5090\u2013100.","journal-title":"Cancer Res"},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"609663","DOI":"10.3389\/fonc.2020.609663","volume":"10","author":"B Xu","year":"2020","unstructured":"Xu B, Li S, Fang Y, Zou Y, Song D, Zhang S, Cai Y. Proprotein convertase Subtilisin\/Kexin type 9 promotes gastric cancer metastasis and suppresses apoptosis by facilitating MAPK signaling pathway through HSP70 Up-Regulation. Front Oncol. 2020;10:609663.","journal-title":"Front Oncol"},{"key":"436_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5114\/aoms.2020.91291","volume":"16","author":"AA Momtazi-Borojeni","year":"2020","unstructured":"Momtazi-Borojeni AA, Nik ME, Jaafari MR, Banach M, Sahebkar A. Effects of immunisation against PCSK9 in mice bearing melanoma. Arch Med Sci. 2020;16:189\u201399.","journal-title":"Arch Med Sci"},{"key":"436_CR13","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2147\/OTT.S129413","volume":"10","author":"SS Gan","year":"2017","unstructured":"Gan SS, Ye JQ, Wang L, et al. Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells. Onco Targets Ther. 2017;10:2139\u201346.","journal-title":"Onco Targets Ther"},{"key":"436_CR14","first-page":"90","volume":"19","author":"M He","year":"2021","unstructured":"He M, Hu J, Fang T, Tang W, Lv B, Yang B, Xia J. Protein convertase subtilisin\/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway. Cancer Biol Med. 2021;19:90\u2013103.","journal-title":"Cancer Biol Med"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep4.1858","volume":"6","author":"GN Ioannou","year":"2022","unstructured":"Ioannou GN, Lee SP, Linsley PS, et al. Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: role of cholesterol. Hepatol Commun. 2022;6:780\u201394.","journal-title":"Hepatol Commun"},{"key":"436_CR16","doi-asserted-by":"publisher","first-page":"e70203","DOI":"10.1111\/1756-185X.70203","volume":"28","author":"CC Cheng","year":"2025","unstructured":"Cheng CC, Shih P-C, Yong SB, Lai EC-C. NHIRD and TriNetX in rheumatology: opportunities and challenges. Int J Rheum Dis. 2025;28:e70203.","journal-title":"Int J Rheum Dis"},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.eclinm.2022.101619","volume":"53","author":"W Wang","year":"2022","unstructured":"Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619.","journal-title":"EClinicalMedicine"},{"key":"436_CR18","first-page":"1244","volume":"4","author":"MG Kahn","year":"2016","unstructured":"Kahn MG, Callahan TJ, Barnard J, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC). 2016;4:1244.","journal-title":"EGEMS (Wash DC)"},{"key":"436_CR19","doi-asserted-by":"publisher","first-page":"e70450","DOI":"10.1111\/1756-185X.70450","volume":"28","author":"H-Y Chen","year":"2025","unstructured":"Chen H-Y, Chang R, Yong S-B, Editorial. The essential role of emulated clinical trial designs in TriNetX studies: avoiding confounding by indication. Int J Rheum Dis. 2025;28:e70450.","journal-title":"Int J Rheum Dis"},{"key":"436_CR20","first-page":"2787","volume":"8","author":"MX Piao","year":"2015","unstructured":"Piao MX, Bai JW, Zhang PF, Zhang YZ. PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways. Int J Clin Exp Pathol. 2015;8:2787\u201394.","journal-title":"Int J Clin Exp Pathol"},{"key":"436_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","volume":"41","author":"L Wang","year":"2022","unstructured":"Wang L, Li S, Luo H, Lu Q, Yu S. PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages. J Exp Clin Cancer Res. 2022;41:303.","journal-title":"J Exp Clin Cancer Res"},{"key":"436_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5114\/aoms.2019.84732","volume":"15","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni AA, Nik ME, Jaafari MR, Banach M, Sahebkar A. Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer. Arch Med Sci. 2019;15:559\u201369.","journal-title":"Arch Med Sci"},{"key":"436_CR23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3892\/etm.2017.4218","volume":"13","author":"X Xu","year":"2017","unstructured":"Xu X, Cui Y, Cao L, Zhang Y, Yin Y, Hu X. PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via Endoplasmic reticulum stress and mitochondrial signaling pathways. Exp Ther Med. 2017;13:1993\u20139.","journal-title":"Exp Ther Med"},{"key":"436_CR24","doi-asserted-by":"publisher","first-page":"119310","DOI":"10.1016\/j.lfs.2021.119310","volume":"273","author":"SA Abuelezz","year":"2021","unstructured":"Abuelezz SA, Hendawy N. HMGB1\/RAGE\/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci. 2021;273:119310.","journal-title":"Life Sci"},{"key":"436_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.5551\/jat.58909","volume":"29","author":"R Nishikawa","year":"2022","unstructured":"Nishikawa R, Furuhashi M, Hori M, et al. A resuscitated case of acute myocardial infarction with both Familial hypercholesterolemia phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes and type I CD36 deficiency. J Atheroscler Thromb. 2022;29:551\u20137.","journal-title":"J Atheroscler Thromb"},{"key":"436_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00210-022-02200-y","volume":"395","author":"H Sun","year":"2022","unstructured":"Sun H, Meng W, Zhu J, Wang L. Antitumor activity and molecular mechanism of proprotein convertase subtilisin\/kexin type 9 (PCSK9) Inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2022;395:643\u201358.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"436_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","volume":"42","author":"Y Gu","year":"2023","unstructured":"Gu Y, Lin X, Dong Y, et al. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. J Exp Clin Cancer Res. 2023;42:2.","journal-title":"J Exp Clin Cancer Res"},{"key":"436_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1593\/neo.121252","volume":"14","author":"X Sun","year":"2012","unstructured":"Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A. Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia. 2012;14:1122\u201331.","journal-title":"Neoplasia"},{"key":"436_CR29","doi-asserted-by":"publisher","first-page":"1142428","DOI":"10.3389\/fimmu.2023.1142428","volume":"14","author":"X Gao","year":"2023","unstructured":"Gao X, Yi L, Jiang C, et al. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Front Immunol. 2023;14:1142428.","journal-title":"Front Immunol"},{"key":"436_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1759-7714.14259","volume":"13","author":"M Xie","year":"2022","unstructured":"Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J, Su C. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer. 2022;13:353\u201360.","journal-title":"Thorac Cancer"},{"key":"436_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","volume":"12","author":"J Yuan","year":"2021","unstructured":"Yuan J, Cai T, Zheng X, et al. Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12:240\u201360.","journal-title":"Protein Cell"},{"key":"436_CR32","doi-asserted-by":"publisher","first-page":"111758","DOI":"10.1016\/j.biopha.2021.111758","volume":"140","author":"K Mahboobnia","year":"2021","unstructured":"Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: rethinking the link. Biomed Pharmacother. 2021;140:111758.","journal-title":"Biomed Pharmacother"},{"key":"436_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"436_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.etap.2019.03.006","volume":"69","author":"V Quagliariello","year":"2019","unstructured":"Quagliariello V, Coppola C, Mita DG, Piscopo G, Iaffaioli RV, Botti G, Maurea N. Low doses of bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of doxorubicin in cardiomyoblasts. Environ Toxicol Pharmacol. 2019;69:1\u20138.","journal-title":"Environ Toxicol Pharmacol"},{"key":"436_CR35","doi-asserted-by":"crossref","unstructured":"Quagliariello V, Bisceglia I, Berretta M, et al. PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: new frontiers in cardioncology. Cancers (Basel). 2023;15(5):1397.","DOI":"10.3390\/cancers15051397"},{"key":"436_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/1756-185X.14197","volume":"24","author":"MK Piya","year":"2021","unstructured":"Piya MK. Metabolic syndrome, rheumatoid and psoriatic arthritis: managing cardiovascular risk. Int J Rheum Dis. 2021;24:1103\u20135.","journal-title":"Int J Rheum Dis"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00436-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:49:26Z","timestamp":1770202166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-025-00436-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00436-0","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}